[illegible]

[illegible]

· [illegible]-[illegible]
· [illegible]
· [illegible]
· [illegible]
· [illegible]
· [illegible]

[illegible] -[illegible]

[illegible] (Yue et al., 2014)[illegible] (Mestas et al., 2004)[illegible] (Walsh et al., 2017)[illegible]

[illegible]

[illegible]
[illegible]T[illegible]B[illegible](NK)[illegible]Jak3[illegible](Nude-J)[illegible] (Panaampon et al., 2021)[illegible]

[illegible](Scid)[illegible] Prkdc[illegible](scid mutation)[illegible]DNA[illegible](DNA-PK)[illegible] VDJ[illegible] DNA[illegible]T[illegible]B[illegible]T[illegible]B[illegible]T[illegible]B[illegible]B[illegible] T[illegible]“[illegible]”(reviewed in Vladutiu, 1993)[illegible]NSG[illegible](NOD)[illegible] (Belizàrio, 2009)[illegible]NOD-scid IL2rg -/-[illegible]NOD/Scid[illegible]IL2rg -/-[illegible] (Belizàrio, 2009)[illegible]
RAG[illegible]rag1[illegible]rag2[illegible]T[illegible]B[illegible]SCID[illegible]RAG[illegible]B[illegible]T[illegible]“[illegible]”[illegible]RAG[illegible] (Mombaerts et al., 1992; Shinkai et al., 1992)[illegible]



[illegible]1[illegible]Rag2/IL2rg [illegible]T [illegible]B [illegible]Rag2/IL2rg[illegible]T[illegible]CD3e (HS-413 108, 1:100)[illegible]B[illegible]CD19 (HS-439 003, 1:100)[illegible]F4/80 (HS-397 008, 1:100)[illegible]Rag2/IL2rg[illegible]B[illegible]T[illegible]Rag2/IL2rg[illegible]F4/80[illegible]

[illegible]

□□□□□□□□□□□CDX□□□□□□□□□□□□□□□□□□□Scid□□□CDX□□□□□□□□□□□□□□□□□□□□□□□□□□□ (Pan et al., 2022)□

□□□□□□□□□□□PDX□□□□□□□□□□□□□□□□□NSG□□□□PDX□□□ (Olson et al., 2018)□□ (Koga et al., 2019)□PDX□□PDX□□□□□□□□□□□□□□□□□□□“□□”□□□□□□□□□□□□□□□□□□□□□□□□□PDX□□□T□□ (Choi et al., 2018)□

□□ (Tian et al., 2020)□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□PBMCs□□□□□□□CD34+□□□ (Olson et al., 2018)□□□PDX□□□□□□□□□□□□□□□□□□□□□□□□□□□

Schematic Illustration of CDX, PDX and Humanized Mice for Human Cancer Research



HistoSure A SySy brand

□ 2□□□□□□□□□□□CDX□PDX □□□□□□□□□□□□□□

□□□□□□□□□□□□□□□□□□□□□□

□□HistoSure□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□

□□□□□□□□□□□□□□□□□□□□□□□□

□□□
HistoSure□□□

Lamin B1□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□Lamin B1□□□□ (reviewed in Evangelisti et al., 2021)□□□□□□□□□□Lamin B1□□□□□□□□□□□□□□□□□□□□□□□□□3A□□

Ki67□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□Ki67□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□3B□□





⊠3a⊠⊠⊠⊠⊠-⊠⊠ Lamin B1 (cat.no. HS-404 017; DAB, ⊠⊠) ⊠⊠⊠-⊠⊠ Lamin B1 (cat.no. HS-404 003; AP-RED, ⊠⊠)⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠

⊠ 3b⊠⊠⊠⊠⊠-⊠⊠ Ki67 (cat.no. HS-398 003; AP-RED, ⊠⊠) ⊠⊠⊠⊠⊠⊠Ki67 (cat.no. HS-398 117; DAB, ⊠⊠)⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠

⊠⊠⊠⊠⊠ 7 (CK7)⊠⊠⊠⊠⊠II⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠HistoSure⊠⊠⊠⊠⊠-CK7⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠CK7⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠



⊠4⊠⊠⊠⊠⊠-⊠⊠⊠⊠⊠ 7 (cat. no. HS-454 017, ⊠⊠⊠⊠ 1:100, DAB)⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠A⊠ ⊠⊠ CK7-⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠B) ⊠⊠⊠CK7-⊠⊠CK7⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠

⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠

(HSCs) (Hess et al., 2020; Curran et al., 2019) (Mian et al., 2021) PBMCs T B NSG B T HSC (reviewed in Curran et al., 2019)

HistoSure

CD45 C 5



5 A Lamin B1 (HS-404 017, 1:100,) B - CD45 (HS-427 003, 1:500,) - CD45 (HS-427 017, 1:100,)DAPI

6CD11b+ CD68+ CD3e+ T



6A Lamin B1 (HS-404 017, 1:100)B - CD45 (HS-427 003, 1:1000) C - CD45 (HS-427 017, 1:100) D - CD11b (HS-384 017, 1:100)E - CD68 (HS-460 017, 1:100) F - CD3e (HS-413 017, 1:750)

[illegible]

[illegible]CD11b[illegible]CD11b+[illegible]CD11b+[illegible]7[illegible]CD11b^{low} F4/80^{high}[illegible]CD11b+ F4/80+(Shan et al., 2020)[illegible]-[illegible]CD11b[illegible]CD11b+[illegible]7[illegible]CD11b+[illegible]7[illegible]



[illegible]7[illegible]-F4/80 (HS-397 008, 1:100)[illegible]-[illegible]CD11b (HS-384 117, 1:100)[illegible]-[illegible]CD11b (HS-384 017, 1:100)[illegible]-[illegible]CD11b (HS-384 117, 1:100; [illegible])[illegible]-[illegible]CD11b (HS-384 017, 1:100; [illegible])[illegible]DAPI[illegible]

[illegible]Christel Bonnas[illegible]
HistoSure[illegible]

Christel [illegible]HistoSure[illegible]

[illegible]

Cat. No.	Product Description	Application	Quantity	Price	Cart

HS-384 017	CD11b, rat, IgG *human specific*	WB IHC-P (FFPE)	200 µl	US$420.00
HS-384 117	CD11b, rat, IgG *mouse specific*	WB IHC IHC-P (FFPE) IHC-Fr	200 µl	US$420.00
HS-439 003	CD19, rabbit, affinity *mouse specific*	WB ICC IHC IHC-P (FFPE)	200 µl	US$375.00
HS-413 108	CD3e, rabbit, recombinant IgG *mouse specific*	IHC IHC-P (FFPE)	100 µl	US$420.00
HS-427 003	CD45, rabbit, affinity *human specific*	WB ICC IHC-P (FFPE)	50 µg	US$375.00
HS-427 017	CD45, rat, IgG *mouse specific*	IHC IHC-P (FFPE) IHC-Fr	200 µl	US$420.00
HS-460 017	CD68, rat, IgG *human specific*	WB ICC IHC IHC-P (FFPE)	200 µl	US$420.00
HS-397 008	F4/80, rabbit, recombinant IgG	WB IHC IHC-P (FFPE)	100 µl	US$420.00
HS-398 003	Ki67, rabbit, affinity *human specific*	IHC-P (FFPE)	200 µl	US$455.00
HS-398 117	Ki67, rat, IgG *mouse specific*	ICC IHC IHC-P (FFPE)	200 µl	US$420.00
HS-404 003	Lamin B1, rabbit, affinity *mouse specific*	WB ICC IHC IHC-P (FFPE)	200 µl	US$375.00
HS-404 017	Lamin B1, rat, IgG *human specific*	WB ICC IHC-P (FFPE)	200 µl	US$420.00

Result count: **12**

□□□□

Yue et al., 2014: A comparative encyclopedia of DNA elements in the mouse genome. PMID: 25409824

Mestas et al., 2004. Of mice and not men: differences between mouse and human immunology. PMID: 14978070

Walsh et al., 2017: Humanized mouse models of clinical disease. PMID: 27959627

Panaampon et al., 2021. Establishment of Nude Mice Lacking NK Cells and Their Application for Human Tumor Xenografts. PMID: 33906298

Vladutiu 1993. The severe combined immunodeficient (SCID) mouse as a model for the study of autoimmune diseases. PMID: 8324894

Belizário 2009. Immunodeficient mouse models: An Overview. DOI: 10.2174/1874226200902010079

Mombaerts et al., 1992. RAG-1-deficient mice have no mature B and T lymphocytes. PMID: 1547488

Shinkai et al., 1992. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. PMID: 1547487

Pan et al., 2022. Patient-derived xenograft models in hepatopancreatobiliary cancer. PMID: 35090441

Choi et al., 2018. Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice.

Olson et al., 2018. Mouse Models for Cancer Immunotherapy Research. PMID: 30309862

Koga et al., 2019. Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid Tumors. PMID: 31064068

Tian et al., 2020. Humanized Rodent Models for Cancer Research. PMID: 33042811

Evangelisti et al., 2021. The wide and growing range of lamin B related diseases: from laminopathies to cancer. PMID: 35132494

Hess et al., 2020. Different Human Immune Lineage Compositions Are Generated in Non-Conditioned NBSGW Mice Depending on HSPC Source. PMID: 33193358

Mian et al., 2021. Advances in Human Immune System Mouse Models for Studying Human Hematopoiesis and Cancer Immunotherapy. PMID: 33603749

Shan et al., 2020. Hepatic Macrophages in Liver Injury. PMID: 32362892